Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Zenas BioPharma (ZBIO) EBIT Margin (2023 - 2025)

Zenas BioPharma has reported EBIT Margin over the past 3 years, most recently at 373.3% for Q1 2025.

  • Quarterly results put EBIT Margin at 373.3% for Q1 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was 793.42% (up 248432.0% YoY), and the annual figure for FY2025 was 793.42%, up 248434.0%.
  • EBIT Margin for Q1 2025 was 373.3% at Zenas BioPharma, up from 1112.46% in the prior quarter.
  • Over the last five years, EBIT Margin for ZBIO hit a ceiling of 71.25% in Q3 2023 and a floor of 1112.46% in Q4 2024.
  • Median EBIT Margin over the past 3 years was 373.3% (2025), compared with a mean of 471.5%.